KRRO (korrobio.com) Rega marang bathi mangsa ngarep
The market trend for Korro Bio, Inc. (KRRO) shown on this price chart reflects the dynamics of a company developing innovative DNA-based medical products, with a PE ratio of 0.00. The business relies on RNA modification to combat hereditary pathologies, protecting its developments with patents. Strong confidence from pharma behemoths and its status as a promising developer ensure sustained investor optimism for the brand.
Rincian analitis lan laporan data perusahaan Korro Bio, Inc (KRRO)
- nilai saham lan prakiraan konsensus rega:
- indikator valuasi pasar bisnis:
- data ekuitas miturut neraca:
- data tingkat utang lan likuiditas finansial:
Total Utang marang Modal Korro Bio, Inc.|KRRO - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Korro Bio, Inc.|KRRO - Utang kumulatif perusahaan|Utang marang nilai buku Korro Bio Inc.|KRRO - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Korro Bio|Likuiditas cepet korrobio.com
- rincian asil keuangan lan kelipatan valuasi:
KRRO - Bathi perusahaan|Proyeksi bathi mangsa ngarep Korro Bio, Inc.|KRRO - Koefisien rega marang bathi|Prakiraan rega marang bathi Korro Bio, Inc.|KRRO - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Korro Bio Inc.|KRRO - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan Korro Bio|KRRO - Bathi saben saham sajroning taun lumaku|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan korrobio.com|KRRO - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Korro Bio, Inc.
Analisis kabeh metrik perusahaan:Korro Bio KRRO
Forward P/E assesses share value relative to expected earnings, helping to distinguish fundamental undervaluation from business degradation. For Korro Bio, Inc. (KRRO), which is in the R&D stage, the calculation is based on predictive models for the future monetization of the OPERA platform. An analysis of the company's future NTM P/E reveals a gap between current capitalization and the potential for inelastic demand for RNA editing. The trend of this metric reflects market expectations regarding development efficiency. This serves as a critical filter to eliminate value traps within a portfolio.
Pesaing langsung
Rega marang bathi mangsa ngarep Tempus Labs (TEM)|QGEN (Qiagen NV) - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Ionis Pharma IONS|Repligen Inc. (RGEN) - Rasio prakiraan rega marang bathi|RNA: Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi CRSP (crisprtx.com)|WGS: Pangali Forward P/E|RARE (Ultragenyx Pharmaceutical Inc.) - Rega marang bathi mangsa ngarep|BEAM (Beam Therapeutics Corp) - Pangali Forward P/E|Sarepta Corp (SRPT) - Kapitalisasi marang proyeksi bathi|Rega marang bathi mangsa ngarep Twist Bioscience (TWST)|TXG - Rasio prakiraan rega marang bathi|Intellia Therapeutics, Inc. - Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi STOK|BioLife Corp - Pangali Forward P/E|Kapitalisasi marang proyeksi bathi Wave Pharma WVE|Maze Therapeutics Inc (MAZE) - Rega marang bathi mangsa ngarep|Rasio rega marang bathi mangsa ngarep SION|PRME (Prime Medicine) - Pangali Forward P/E|Prakiraan rega marang bathi Taysha Gene Therapies Inc (TSHA)|Prakiraan rega marang bathi QURE (uniQure Corp)|Kapitalisasi marang proyeksi bathi MeiraGTx Corp|Rega marang bathi mangsa ngarep REGENXBIO Inc. RGNX|Pangali Forward P/E solidbio.com SLDB|OCGN - Rega marang bathi mangsa ngarep|Pangali mangsa ngarep rega marang bathi PACB (Pacific Biosciences of California, Inc.)|Benitec (BNTC) - Rega marang bathi mangsa ngarep|Design Corp - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Rocket Pharmaceuticals|Rasio prakiraan rega marang bathi 4dmoleculartherapeutics.com FDMT|Pangali Forward P/E LXEO|Editas Medicine Inc - Rasio rega marang bathi mangsa ngarep|Rega marang bathi mangsa ngarep Silence Therapeutics Inc. SLN|PRQR: Rasio rega marang bathi mangsa ngarep|Codexis Bio - Pangali Forward P/E|SGMO - Pangali Forward P/E|nautilus.bio (NAUT) - Rega marang bathi mangsa ngarep|Metagenomi Inc. (MGX) - Pangali Forward P/E|Rega marang bathi mangsa ngarep Precision BioSciences, Inc.|Rasio prakiraan rega marang bathi Generation Bio Corp GBIO|Rega marang bathi mangsa ngarep Boundless Bio, Inc. (BOLD)|XCUR (exicuretx.com) - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Imunon IMNN|Pangali mangsa ngarep rega marang bathi PHIO|MBIO - Rega marang bathi mangsa ngarep|Rasio prakiraan rega marang bathi TransCode Therapeutics|BNGO (bionanogenomics.com) - Prakiraan rega marang bathi|adnas.com - Pangali mangsa ngarep rega marang bathi|BLUE (bluebird bio) - Pangali Forward P/E|Rega marang bathi mangsa ngarep IPA|Pangali Forward P/E OMGA|Kapitalisasi marang proyeksi bathi Singular Genomics Corp|Rega marang bathi mangsa ngarep Regulus Therapeutics RGLS|syros.com (SYRS) - Rasio prakiraan rega marang bathi|TBIO: Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi TCON (TRACON Pharmaceuticals Inc.)|UBX: Pangali Forward P/E
